Welcome to our dedicated page for Goldenwell SEC filings (Ticker: GWLL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Goldenwell's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Goldenwell's regulatory disclosures and financial reporting.
Goldenwell Biotech, Inc. reported no revenue for the quarter ended March 31, 2026 and a net loss of $17,606, an improvement from a $38,536 loss a year earlier. Operating expenses were $31,335, partly offset by $15,829 of other income, including legal settlement and breakage income.
The company had cash of $13,414 and total assets of $18,754 against total liabilities of $380,073, resulting in stockholders’ deficit of $361,319. Management discloses substantial doubt about its ability to continue as a going concern, citing an accumulated deficit of $1,673,722 and dependence on raising additional capital.
Goldenwell estimates it needs about $5,000,000 to build manufacturing capacity and scale operations and plans to seek debt or equity financing, though no arrangements are in place. The company also restated prior 2025 quarterly figures to correct the timing of a $4,160 legal expense accrual.
Goldenwell Biotech, Inc. reports minimal 2025 revenue of $55 from nutraceutical and dietary supplement products and a net loss of $296,471, reflecting very early-stage operations. The company has no active operating facilities and uses its Ohio address only for mail.
As of December 31, 2025, Goldenwell held cash of $26,775, total assets of $36,120, total liabilities of $379,833, and a stockholders’ deficit of $343,713. Management and the auditor highlight substantial doubt about the company’s ability to continue as a going concern. Goldenwell estimates it needs about $5,000,000 and roughly one year to build manufacturing capacity, but currently relies on related-party loans and has three non-employee officers, material weaknesses in internal controls, no independent directors, and no formal cybersecurity risk processes.
Goldenwell Biotech, Inc. filed an amended quarterly report for the period ended September 30, 2025 to fully restate its financial statements after its auditor identified material GAAP errors. The restatement removed $25,000 of service revenue, added a $13,350 prepaid OTCQB fee asset, and adjusted legal fees, increasing Q3 2025 net loss from $7,985 to $27,895.
For the nine months ended September 30, 2025, the company reported no revenue and a net loss of $96,731, bringing its accumulated deficit to $1,456,377. At September 30, 2025, cash was $45,622, total assets were $233,760, total liabilities were $377,733, and stockholders’ equity was a deficit of $143,974. A related-party loan totaled $95,588, and management disclosed substantial doubt about the company’s ability to continue as a going concern.
Goldenwell Biotech, Inc. filed Amendment No. 1 to its quarterly report for the period ended June 30, 2025 to fully restate its financial statements and related disclosures. The restatement reverses previously recorded service revenue and reclassifies certain legal and OTC Markets fees to comply with US GAAP.
For the six months ended June 30, 2025, the Company generated no revenue and recorded a net loss of $68,836, bringing its accumulated deficit to $1,428,481. At June 30, 2025, Goldenwell reported cash of $76,507, total assets of $267,315, total liabilities of $383,393, and stockholders’ deficit of $116,079, and its auditors and management highlighted substantial doubt about its ability to continue as a going concern.
Goldenwell Biotech, Inc. filed an amended quarterly report to fully restate its financial statements for the quarter ended March 31, 2025 after determining earlier figures could no longer be relied upon. The restatement mainly records a previously unaccrued legal fee, increasing legal expense by $4,160 and raising the quarterly net loss to $38,536.
For the quarter, the company generated no revenue, incurred $36,436 in general and administrative costs and reported a basic and diluted loss per share of zero on 99,000,000 shares. Cash was $17,127 against current liabilities of $277,693, resulting in stockholders’ deficit of $85,778 and an accumulated deficit of $1,398,181.
Management discloses substantial doubt about the company’s ability to continue as a going concern, citing ongoing losses, lack of revenue and reliance on capital raising. The company has a $95,599 related-party long-term loan and estimates it will need about $5,000,000 to build manufacturing capacity and scale its nutraceutical and supplement business.
Goldenwell Biotech, Inc. is alerting investors that certain prior quarterly financial statements should no longer be relied upon and will be restated to correct accounting errors. Its auditor determined a $9,840 legal invoice covering services from May 21, 2024 to September 23, 2025 was recorded in the wrong periods.
The company plans to amend its March 31, 2025 Form 10‑Q to recognize $2,280 of legal fees, its June 30, 2025 Form 10‑Q to recognize $2,200, and its September 30, 2025 Form 10‑Q to recognize $2,080. Goldenwell also identified errors in the timing of revenue recognition on a service contract and misclassified prepaid fees to OTC Markets Group, Inc. that should have been deferred and amortized over the contract term.
Because of these issues, the company states that the financial statements in its March 31, June 30, and September 30, 2025 Forms 10‑Q should not be relied upon insofar as they relate to the legal expenses accrued over that period. Goldenwell has discussed the matter with its independent registered public accounting firm, Michael Gillespie & Associates, PLLC, and expects to complete the restatements around June 30, 2026.
Goldenwell Biotech, Inc. notifies the SEC it could not timely file its Quarterly Report on Form 10-Q for the period ended March 31, 2026. The company states it was unable, without unreasonable effort or expense, to compile the financial statements and related disclosures and expects to file on or before May 19, 2026.
The notification, signed by Hua Xie, Secretary and principal accounting officer, also notes the Annual Report on Form 10-K for the year ended March 31, 2026 has not been filed.
Goldenwell Biotech, Inc. notifies the SEC it will not timely file its Annual Report on Form 10-K for the fiscal year ended December 31, 2025. The company states it could not, "without unreasonable effort or expense," compile all required financial statements and related disclosures and expects to file the report on or before April 15, 2026. The notice is signed by CEO Shuang Liu.
Goldenwell Biotech, Inc. reports third-quarter 2025 results that highlight its early-stage status and financial strain. For the quarter ended September 30, 2025, the company generated $25,000 in service revenue and no product sales, leading to a net loss of $7,985. For the first nine months of 2025, revenue from services was $62,500 and the net loss was $47,581, an improvement from a $103,962 loss a year earlier.
As of September 30, 2025, Goldenwell held $45,622 in cash, total assets of $220,410 and total liabilities of $315,233, resulting in negative stockholders’ equity of $94,823. The company has an accumulated deficit of $1,407,226 and a $95,588 related-party loan from its chief executive officer. Management and the auditors state that these conditions raise substantial doubt about the company’s ability to continue as a going concern, and the business will require significant new financing to pursue its plan to scale nutraceutical and dietary supplement operations.
Goldenwell Biotech, Inc. reports minimal early-stage operations and continuing losses for the quarter and six months ended June 30, 2025. The company generated mainly service revenue of $37,500 in the six-month period, with only negligible product sales, and recorded a net loss of $39,596, bringing its accumulated deficit to $1,399,241 since inception.
At June 30, 2025, Goldenwell had total assets of $251,295, including cash of $76,507 and inventory of $174,788, against total liabilities of $350,633, resulting in negative stockholders’ equity. Management discloses a working capital deficit and an outstanding related-party loan of $95,588, and states that substantial doubt exists about the company’s ability to continue as a going concern.
The company plans to expand its nutraceutical and dietary supplements business but estimates it will need about $5,000,000 to build manufacturing facilities and scale operations. Management indicates that additional capital will likely need to come from debt or equity offerings, with no assurance such financing can be obtained.